Relationship between nonalcoholic fatty liver disease markers and renal function in patients with type 1 diabetes;Povezanost markera nealkoholne bolesti jetre s parametrima bubrežne funkcije u tipu 1 šećerne bolesti

Acta Medica Croatica

Volumn 65, Issue SUPP 3, 2011, Pages 6-10

  Bulum, Tomislav ^a   Duvnjak, Lea ^a,b  

^a University of Zagreb   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Nonalcoholic fatty liver disease; Renal function; Type 1 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; CREATININE; FERRITIN; GAMMA GLUTAMYLTRANSFERASE;

ARTICLE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CREATININE URINE LEVEL; DISEASE ASSOCIATION; DISEASE MARKER; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; NONALCOHOLIC FATTY LIVER;

ADULT; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; FATTY LIVER; FEMALE; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED;

EID: 84862907339     PISSN: 13300164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease. Lancet 2010; 75: 1296-1309.
2. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function - measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473-83.
3. Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S. Body mass indeks and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 2004; 65: 1870-6.
4. Go A, Chertow G, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
5. Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci 2005; 50: 171-80.
6. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos Nutrition and Liver Study. Hepatology 2005; 42: 44-52.
7. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-50.
8. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009; 49: 306-17.
9. Borch-Johnsen K, Kreiner S. Proteinuria: Value as a predictor of cardiovascular mortality in insulin dependent diabetes mellitus. BMJ 1987; 294: 1651-4.
10. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R i sur. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-23.
11. Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Fiorello S i sur. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2005; 1578-82.
12. Arase Y, Suzuki F, Kobayashi M, Suzuki Y, Kawamura Y, Matsumoto i sur. The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease. Intern Med 2011; 50: 1081-7.
13. Chang Y, Ryu S, Sung E, Woo HY, Oh E, Cha K i sur. Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metabolism 2008; 57: 569-76.
14. Targher G, Chonchol M, Zoppini G, Abaterusso C, Bonora E. Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: Is there a link? J Hepatol 2011; 54: 1020-9.
15. Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day C i sur. Non-alcoholic fatty liver disease in independently associated with an increased prevalence of chronic kidney disease and proliferative/laser treated retinopathy in type 2 diabetic patients. Diabetologia 2008; 51: 444-50.
16. Targher G, Bertolini L, Chonchol M, Rodella S, Zoppini G, Lippi G i sur. Nonalcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retiniopathy in type 1 diabetic patients. Diabetologia 2010; 53: 1341-8.
17. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98: 960-7.
18. Targher G, Kendrick J, Smith G, Chonchol M. Relationship between serum gamma-glutamyltransferase concentrations and chronic kidney disease in the United States population. Findings from the National Health and Nutrition Examination Survey 2001-2006. Nutr Metab Cardiovasc Dis 2010; 20: 583-90.
19. Targher G, Bosworth C, Kendrick J, Smith G, Lippi G, Chonchol M. Relationship of serum bilirubin concentrations to kidney function and albuminuria in the United States population. Findings from the National Health and Nutrition Examination Survey 2001-2006. Clin Chem Lab Med 2009; 47; 1055-62.
20. Yun KE, Shin CY, Yoon YS, Park HS. Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans. Atherosclerosis 2009; 205; 533-7.
21. Pinto-Sietsma SJ, Janssen WMT, Hillege HL, Navis G, de Zeeuw D, de Jong PE i sur. A central body fat distribution is related to renal function impairment, even in lean subjects. A m J Kidney Dis 2003; 41: 733-41.
22. Fan JG, Zhu J, Li XJ, Chen L, Lu YS, Li L i sur. Fatty liver and the metabolic syndrome among Shanghai adults. J Gastroenterol Hepatol 2005; 20: 1825-32.
23. Bulum T, Kolarić B, Duvnjak L, Duvnjak M. Nonalcoholic fatty liver disease markers are associated with insulin resistance in type 1 diabetes. Dig Dis Sci 2011, doi: 10.1007/s10620-011-1807-7.
24. Marchesini G, Moscatiello S, Di Domizio S, Forlani G. Obesity-associated liver disease. J Clin Endocrinol Metab 2008; 93 (Suppl 1): S74-80.
25. Tilg H, Moschen AR. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab 2008; 19: 371-9.
26. Fried L, Solomon C, Shlipak M, Seliger S, Stehman-Breen C, Bleyer AJ i sur. Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals. J Am Soc Nephrol 2004; 15: 3184-91.
27. Kronenberg F. Emerging risk factors and markers of chronic kidney disease progression. Nat Rev Nephrol 2009; 5: 677-89.
28. Vlassara H, Torreggiani M, Post JB, Zheng F, Uribarri J, Striker GE. Role of oxidants/inflammation in declining renal function in chronic kidney disease and normal aging. Kidney Int 2009; 114 (Suppl.): S3-11.
29. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 365 (2005) 1415-28.
30. Cheng AY, Kong AP, Wong VW, So WY, Chan HL, Ho CS i sur. Chronic hepatitis B viral infection independently predicts renal outcome in type 2 diabetic patients. Diabetologia 2006; 49: 1777-84.
31. Targher G, Chonchol M, Bertolini L, Rodella S, Zenari L, Lippi G i sur. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol 2008; 19: 1564-70.
32. Hwang ST, Cho YK, Yun JW, Park JH, Kim HJ, Park DI i sur. Impact of NA FLD on microalbuminuria in patients with prediabetes and diabetes. Intern Med J 2010; 40: 437-42.
33. Yilmaz Y, Alahbad YO, Yonal O, Kurt R, Kedrah AE, Celikel CA i sur. Microalbuminuria in nondiabetic patients with non-alcoholic fatty liver disease: association with liver fibrosis. Metabolism 2010; 59: 1327-30.